ELVN

Enliven Therapeutics (ELVN)

About Enliven Therapeutics (ELVN)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Details

Daily high

$61.76

Daily low

$59.73

Price at open

$60.18

52 Week High

$62.32

52 Week Low

$14.78

Market cap

4.3B

Dividend yield

0.00%

Volume

249,675

Avg. volume

996,046

P/E ratio

-36.12

Enliven Therapeutics News